Ultragenyx Pharmaceutical Inc. (RARE)
Stock Price:
$118.54 USD
-3.88 (-3.17%)
Updated November 30, 4:00 PM EST - Market closed
Key Info
| Market Cap |
7.24B |
| Revenue (ttm) |
215.08M |
| Net Income (ttm) |
-256.36M |
| Shares Out |
61.04M |
| EPS (ttm) |
-4.34 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 30 |
| Last Price |
$118.54 |
| Previous Close |
$122.42 |
| Change ($) |
-3.88 |
| Change (%) |
-3.17% |
| Day's Open |
122.56 |
| Day's Range |
117.52 - 124.54 |
| Day's Volume |
529,435 |
| 52-Week Range |
33.80 - 124.54 |
More Stats
| Market Cap |
7.24B |
| Enterprise Value |
6.51B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
61.04M |
| Float |
n/a |
| EPS (basic) |
-4.38 |
| EPS (diluted) |
-4.34 |
| FCF / Share |
-2.89 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.84M |
| Short Ratio |
12.50 |
| Short % of Float |
n/a |
| Beta |
2.16 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
33.64 |
| PB Ratio |
11.90 |
| Revenue |
215.08M |
| Operating Income |
-328.00M |
| Net Income |
-256.36M |
| Free Cash Flow |
-175.27M |
| Net Cash |
728.85M |
| Net Cash / Share |
11.94 |
| Gross Margin |
-122.12% |
| Operating Margin |
-152.50% |
| Profit Margin |
-119.20% |
| FCF Margin |
-81.49% |
| ROA |
-19.11% |
| ROE |
-36.80% |
| ROIC |
-42.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (16)
| Buy |
10 |
| Overweight |
1 |
| Hold |
5 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$107.06*
(-9.68% downside)
Low
64.0
Current: $118.54
High
128.0
Target: 107.06
*Average 12-month price target from 16 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 104 | 51.50 | 2.61 | 0.13 | - | - | - | - | - |
| Revenue Growth | 101.41% | 1871.48% | 1863.91% | - | - | - | - | - | - |
| Gross Profit | 94.71 | 50.35 | 2.61 | 0.13 | - | - | - | - | - |
| Operating Income | -424 | -371 | -329 | -248 | -148 | -56.78 | -32.28 | -15.99 | -6.56 |
| Net Income | -403 | -198 | -302 | -246 | -146 | -64.61 | -50.29 | -19.56 | -7.47 |
| Shares Outstanding | 56.58 | 49.78 | 42.45 | 39.59 | 36.78 | 28.76 | 3.38 | 1.38 | 1.62 |
| Earnings Per Share | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.25 | -14.87 | -14.20 | -4.62 |
| Operating Cash Flow | -345 | -291 | -254 | -161 | -106 | -44.63 | -31.20 | -12.50 | -5.83 |
| Capital Expenditures | -24.83 | -4.08 | -2.79 | -10.19 | -4.96 | -2.15 | -0.41 | -1.09 | -0.55 |
| Free Cash Flow | -370 | -295 | -257 | -171 | -111 | -46.78 | -31.61 | -13.60 | -6.37 |
| Cash & Equivalents | 755 | 460 | 234 | 384 | 439 | 188 | 53.83 | 86.67 | - |
| Total Debt | 29.76 | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 725 | 460 | 234 | 384 | 439 | 188 | 53.83 | 86.67 | - |
| Assets | 1,135 | 720 | 491 | 541 | 560 | 198 | 59.65 | 88.32 | - |
| Liabilities | 482 | 111 | 107 | 66.65 | 28.48 | 13.02 | 9.54 | 3.98 | - |
| Book Value | 654 | 609 | 383 | 474 | 531 | 185 | -74.82 | -27.05 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Ultragenyx Pharmaceutical Inc. |
| Country |
United States |
| Employees |
740 |
| CEO |
Emil D. Kakkis |
Stock Information
| Ticker Symbol |
RARE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RARE |
| IPO Date |
January 31, 2014 |
Description
Ultragenyx Pharmaceutical, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.